search
Back to results

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Primary Purpose

Solid Tumors Harboring NTRK Fusion

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Selitrectinib (BAY2731954)
Sponsored by
Bayer
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Solid Tumors Harboring NTRK Fusion focused on measuring Metastatic cancer, Advanced cancer, Neurotrophic tyrosine receptor kinase (NTRK), NTRK1, NTRK2, NTRK3, Fusion Positive, Children, Loxo-195

Eligibility Criteria

1 Month - undefined (Child, Adult, Older Adult)All Sexes

Inclusion Criteria:

  • Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
  • Previous treatment with a kinase inhibitor with known activity on TRK inhibition
  • Unable to participate in an ongoing selitrectinib clinical trial
  • Medically suitable for treatment with selitrectinib

Exclusion Criteria:

  • Currently enrolled in an ongoing clinical study with a TRK inhibitor

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    June 29, 2017
    Last Updated
    September 8, 2021
    Sponsor
    Bayer
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03206931
    Brief Title
    Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
    Official Title
    Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    September 2021
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Bayer

    4. Oversight

    5. Study Description

    Brief Summary
    Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Solid Tumors Harboring NTRK Fusion
    Keywords
    Metastatic cancer, Advanced cancer, Neurotrophic tyrosine receptor kinase (NTRK), NTRK1, NTRK2, NTRK3, Fusion Positive, Children, Loxo-195

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Selitrectinib (BAY2731954)
    Other Intervention Name(s)
    Loxo-195
    Intervention Description
    Selitrectinib is administered as capsules or liquid formulation.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Month
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion Previous treatment with a kinase inhibitor with known activity on TRK inhibition Unable to participate in an ongoing selitrectinib clinical trial Medically suitable for treatment with selitrectinib Exclusion Criteria: Currently enrolled in an ongoing clinical study with a TRK inhibitor

    12. IPD Sharing Statement

    Learn more about this trial

    Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

    We'll reach out to this number within 24 hrs